Secor Capital Advisors’s Cytokinetics CYTK Stock Holding History

Secor Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-35,697	Closed	-$291K	–	537
2017 Q4	$291K	Buy	+35,697	New	+$405K	0.01%	421

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Secor Capital Advisors's CYTK Position: Q1 2018 in Review

Secor Capital Advisors sold out of Cytokinetics (CYTK) in Q1 2018, closing a stake of 35,697 shares — an estimated $291K sold.

Secor Capital Advisors first reported a position in CYTK in Q4 2017 and held it in 1 quarter. The position peaked at $291K in Q4 2017. 127 funds tracked by Wall St. Rank hold CYTK as of Q1 2018.

Secor Capital Advisors reported no remaining Cytokinetics position as of Q1 2018 after selling out during the quarter.
Secor Capital Advisors sold 35,697 Cytokinetics shares in Q1 2018, an estimated $291K.
Secor Capital Advisors first reported a position in Cytokinetics in Q4 2017 and held it in 1 quarter.
Secor Capital Advisors's Cytokinetics position peaked at $291K in Q4 2017.
127 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2018.

Based on Secor Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.